Have you bought these medications in New York? Find out if you’re entitled to compensation for being overcharged after a recent court order
New York Attorney General Letitia James and a coalition of state officials have secured a $25 million settlement against pharmaceutical company Glenmark. This action concludes a legal challenge regarding allegations that various drug manufacturers coordinated to fix supply levels and inflate costs for generic medications. Consumers who purchased specific prescription or over-the-counter drugs between 2009 and 2019 may be eligible for financial compensation.
The list of impacted medications covers more than one hundred items. Common drugs included in this settlement range from treatments for ADHD and arthritis to birth control and antibiotics. Medications such as Ritalin, Adderall, Prozac, and Flonase are among those identified in the court filings. The legal action followed reports of industry executives engaging in coordinated efforts to limit competition and drive up prices through private communication channels.
Claimants do not need physical receipts to file an initial registration for the settlement. Interested parties can visit the official attorney general portal to register their contact information. Those with records of larger purchases may upload documentation to support a claim for a higher payout amount. Registration serves as the first step for potential recipients to receive updates as the claims process advances.
This settlement marks a significant development for New Yorkers who relied on these generic medications for chronic conditions like diabetes, hypertension, and asthma. The $1.8 million specifically allocated to New York residents represents part of a broader effort to provide restitution for consumers harmed by industry collusion. Officials indicate that additional settlements involving other companies remain possible, which could further influence the final compensation figures.
Individuals should visit the official website for the generic drugs settlement to confirm eligibility. The portal provides the full list of qualifying medications and clear instructions on how to submit a registration form. Taking action now ensures that claimants remain informed as administrators finalize the distribution of funds.